{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:32Z","timestamp":1781639732777,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gansu Provincial Youth Science and Technology Fund","award":["No. 24JRRA1067"],"award-info":[{"award-number":["No. 24JRRA1067"]}]},{"name":"Gansu Provincial Department of Science and Technology Project","award":["No. 25JRRA886"],"award-info":[{"award-number":["No. 25JRRA886"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteosarcoma of the jaw is a rare clinical entity characterized by a high propensity for local recurrence, for which surgical resection serves as the primary treatment modality. However, achieving negative margins in the maxilla is often complicated by the proximity of critical neurovascular and orbital structures. Furthermore, in certain emergency scenarios, surgical compromises may precipitate suboptimal initial control and rapid disease progression. This presents a significant therapeutic dilemma, particularly given the lack of standardized management guidelines for refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 37-year-old male underwent emergency orbital decompression for a vision-threatening maxillary mass. One month later, rapid recurrence near the skull base compressed the optic nerve. Due to the risks of hemorrhage and iatrogenic neural injury from re-biopsy, and the patient\u2019s refusal to accept the risk of jeopardizing his preserved vision, a diagnosis of clinicoradiological recurrence was established based on multiparametric MRI (specifically quantitative ADC analysis) and multidisciplinary consensus. The patient received salvage therapy comprising radiotherapy, chemotherapy, and Anlotinib. Over a 48-month follow-up period, the patient achieved complete radiological remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the emergency intervention successfully preserved vision, it also highlights the risks of deviating from standard oncologic principles, which likely precipitated the rapid recurrence. However, the primary significance of this report is to demonstrate that in refractory cases where salvage surgery is contraindicated, an aggressive multimodal strategy\u2014integrating radiotherapy, chemotherapy, and Anlotinib\u2014may serve as a viable salvage option. These findings warrant further validation in prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-026-08027-w","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:34:37Z","timestamp":1772771677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term clinical remission in rapidly recurrent maxillary osteosarcoma treated with anlotinib-based multimodal therapy: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Xinru","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"8027_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbiomolbio.2025.07.001","volume":"197","author":"X Wang","year":"2025","unstructured":"Wang X, Zhu K, Hu J, Zhang C. Advances and challenges in the treatment of osteosarcoma. Prog Biophys Mol Biol. 2025;197:60\u201374.","journal-title":"Prog Biophys Mol Biol"},{"key":"8027_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1750-1172-2-6","volume":"2","author":"P Picci","year":"2007","unstructured":"Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"8027_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/clinpract14030077","volume":"14","author":"J Rodriguez-Molinero","year":"2024","unstructured":"Rodriguez-Molinero J, Pozo-Kreilinger JJ, Ruiz-Roca JA, Lopez-Sanchez AF, Cebrian-Carretero JL. Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study. Clin Pract. 2024;14(3):965\u201379.","journal-title":"Clin Pract"},{"issue":"5","key":"8027_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaoto.2015.0340","volume":"141","author":"RJ Lee","year":"2015","unstructured":"Lee RJ, Arshi A, Schwartz HC, Christensen RE. Characteristics and prognostic factors of osteosarcoma of the jaws: a retrospective cohort study. JAMA Otolaryngol Head Neck Surg. 2015;141(5):470\u20137.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"8027_CR5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cncr.10849","volume":"95","author":"SG Patel","year":"2002","unstructured":"Patel SG, Meyers P, Huvos AG, Wolden S, Singh B, Shaha AR, Boyle JO, Pfister D, Shah JP, Kraus DH. Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer. 2002;95(7):1495\u2013503.","journal-title":"Cancer"},{"issue":"14","key":"8027_CR6","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1002\/cncr.24297","volume":"115","author":"BA Guadagnolo","year":"2009","unstructured":"Guadagnolo BA, Zagars GK, Raymond AK, Benjamin RS, Sturgis EM. Osteosarcoma of the jaw\/craniofacial region: outcomes after multimodality treatment. Cancer. 2009;115(14):3262\u201370.","journal-title":"Cancer"},{"key":"8027_CR7","doi-asserted-by":"publisher","unstructured":"Zhang L, Guo Y, Sumita Y, Hirai H, Yamazaki M, Hayashi T, et al. Does chemotherapy improve the prognosis in patients with jaw osteosarcoma? A systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2026;55(1):10\u201319. https:\/\/doi.org\/10.1016\/j.ijom.2025.09.008 Epub 2025 Sep 29. PMID: 41027777.","DOI":"10.1016\/j.ijom.2025.09.008"},{"issue":"2","key":"8027_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.oraloncology.2013.10.017","volume":"50","author":"D Baumhoer","year":"2014","unstructured":"Baumhoer D, Brunner P, Eppenberger-Castori S, Smida J, Nathrath M, Jundt G. Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry. Oral Oncol. 2014;50(2):147\u201353.","journal-title":"Oral Oncol"},{"key":"8027_CR9","doi-asserted-by":"publisher","first-page":"1283932","DOI":"10.3389\/fonc.2023.1283932","volume":"13","author":"Q Chen","year":"2023","unstructured":"Chen Q, Zheng K, Xu M, Yan N, Hai G, Yu X. Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review. Front Oncol. 2023;13:1283932.","journal-title":"Front Oncol"},{"issue":"4","key":"8027_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G Wang","year":"2019","unstructured":"Wang G, Sun M, Jiang Y, Zhang T, Sun W, Wang H, Yin F, Wang Z, Sang W, Xu J, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019;145(4):979\u201393.","journal-title":"Int J Cancer"},{"issue":"5","key":"8027_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s10637-020-00912-7","volume":"38","author":"Z Tian","year":"2020","unstructured":"Tian Z, Liu H, Zhang F, Li L, Du X, Li C, Yang J, Wang J. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma. Invest New Drugs. 2020;38(5):1559\u201369.","journal-title":"Invest New Drugs"},{"issue":"1","key":"8027_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.","journal-title":"J Hematol Oncol"},{"issue":"15suppl","key":"8027_CR13","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.1200\/JCO.2020.38.15_suppl.11525","volume":"38","author":"L Tang","year":"2020","unstructured":"Tang L, Niu X, Wang Z, Cai Q, Tu C, Fan Z, Yao Y. A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor. J Clin Oncol. 2020;38(15suppl):11525\u201311525.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8027_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10637-020-01015-z","volume":"39","author":"J Liu","year":"2021","unstructured":"Liu J, Deng YT, Jiang Y. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. Invest New Drugs. 2021;39(2):330\u20136.","journal-title":"Invest New Drugs"},{"key":"8027_CR15","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.jbo.2024.100594","volume":"45","author":"Q Meng","year":"2024","unstructured":"Meng Q, Han J, Wang P, Jia C, Guan M, Zhang B, Zhao W. BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR\/Ras\/CDK2 pathway. J Bone Oncol. 2024;45:100594.","journal-title":"J Bone Oncol"},{"key":"8027_CR16","doi-asserted-by":"publisher","unstructured":"El Motassime A, Vitiello R, Comodo RM, Capece G, Bocchino G, Bocchi MB, et al. Osteosarcoma: a comprehensive morphological and molecular review with prognostic implications. Biology (Basel). 2025;14(10):1407. https:\/\/doi.org\/10.3390\/biology14101407. PMID: 41154810; PMCID: PMC12561861.","DOI":"10.3390\/biology14101407"},{"key":"8027_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4137\/CPath.S582","volume":"1","author":"LJ Layfield","year":"2008","unstructured":"Layfield LJ, Emerson L, Crim JR, Randall L. Squamous differentiation and cytokeratin expression in an osteosarcoma: a case report and review of the literature. Clin Med Pathol. 2008;1:55\u20139.","journal-title":"Clin Med Pathol"},{"issue":"10","key":"8027_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/jcp.56.10.742","volume":"56","author":"K Okada","year":"2003","unstructured":"Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E. Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol. 2003;56(10):742\u20136.","journal-title":"J Clin Pathol"},{"key":"8027_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1477-7819-12-365","volume":"12","author":"T Wang","year":"2014","unstructured":"Wang T, Wu X, Cui Y, Chu C, Ren G, Li W. Role of apparent diffusion coefficients with diffusion-weighted magnetic resonance imaging in differentiating between benign and malignant bone tumors. World J Surg Oncol. 2014;12:365.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"8027_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1148\/radiol.13130844","volume":"271","author":"F Del Grande","year":"2014","unstructured":"Del Grande F, Subhawong T, Weber K, Aro M, Mugera C, Fayad LM. Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 T. Radiology. 2014;271(2):499\u2013511.","journal-title":"Radiology"},{"issue":"8","key":"8027_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/01.rli.0000225398.17315.68","volume":"41","author":"M Uhl","year":"2006","unstructured":"Uhl M, Saueressig U, van Buiren M, Kontny U, Niemeyer C, K\u00f6hler G, Ilyasov K, Langer M. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006;41(8):618\u201323.","journal-title":"Invest Radiol"},{"issue":"3 Pt 1","key":"8027_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/00005537-200003000-00009","volume":"110","author":"EM Merkle","year":"2000","unstructured":"Merkle EM, Lewin JS, Aschoff AJ, Stepnick DW, Duerk JL, Lanzieri CF, Strauss M. Percutaneous magnetic resonance image-guided biopsy and aspiration in the head and neck. Laryngoscope. 2000;110(3 Pt 1):382\u20135.","journal-title":"Laryngoscope"},{"issue":"1","key":"8027_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijom.2020.05.007","volume":"50","author":"JH Zhu","year":"2021","unstructured":"Zhu JH, Yang R, Guo YX, Wang J, Liu XJ, Guo CB. Navigation-guided core needle biopsy for skull base and parapharyngeal lesions: a five-year experience. Int J Oral Maxillofac Surg. 2021;50(1):7\u201313.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"8027_CR24","doi-asserted-by":"publisher","first-page":"1669974","DOI":"10.3389\/fonc.2025.1669974","volume":"15","author":"JH Zhu","year":"2025","unstructured":"Zhu JH, Liu XJ. Robotic assistance for skull base biopsy: a feasibility study in phantom and cadaver. Front Oncol. 2025;15:1669974.","journal-title":"Front Oncol"},{"key":"8027_CR25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer (Version 1.2021). Plymouth Meeting (PA): National Comprehensive Cancer Network; 2020. Available from: https:\/\/www.nccn.org. Cited 6 Feb 2026."},{"issue":"3","key":"8027_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0305-7372(93)90036-Q","volume":"19","author":"AP Launchbury","year":"1993","unstructured":"Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993;19(3):197\u2013228.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"8027_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/0019-509X.52958","volume":"46","author":"T Azizi","year":"2009","unstructured":"Azizi T, Motamedi MH, Jafari SM. Gnathic osteosarcomas: a 10-year multi-center demographic study. Indian J Cancer. 2009;46(3):231\u20133.","journal-title":"Indian J Cancer"},{"issue":"1","key":"8027_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jnci.2018.02.001","volume":"30","author":"MA ElKordy","year":"2018","unstructured":"ElKordy MA, ElBaradie TS, ElSebai HI, KhairAlla SM, Amin AAE. Osteosarcoma of the jaw: Challenges in the diagnosis and treatment. J Egypt Natl Canc Inst. 2018;30(1):7\u201311.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"4","key":"8027_CR29","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/jnci\/djae229","volume":"117","author":"MD Danese","year":"2025","unstructured":"Danese MD, Groundland JS. Effect of chemotherapy and surgery timing on mortality in upper and lower extremity osteosarcoma. J Natl Cancer Inst. 2025;117(4):611\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"8027_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","volume":"15","author":"JS Biermann","year":"2017","unstructured":"Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, et al. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15(2):155\u201367.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"8027_CR31","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1111\/ajco.13916","volume":"19","author":"H Li","year":"2023","unstructured":"Li H, Li Y, Song L, Ai Q, Zhang S. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy. Asia Pac J Clin Oncol. 2023;19(5):e314\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"8027_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5306\/wjco.v11.i6.370","volume":"11","author":"D Zhao","year":"2020","unstructured":"Zhao D, Xie B, Yang Y, Yan P, Liang SN, Lin Q. Progress in immunotherapy for small cell lung cancer. World J Clin Oncol. 2020;11(6):370\u20137.","journal-title":"World J Clin Oncol"},{"issue":"11","key":"8027_CR33","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cam4.4613","volume":"11","author":"RS Zhang","year":"2022","unstructured":"Zhang RS, Liu J, Deng YT, Wu X, Jiang Y. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era. Cancer Med. 2022;11(11):2271\u201383.","journal-title":"Cancer Med"},{"key":"8027_CR34","doi-asserted-by":"publisher","first-page":"1703261","DOI":"10.3389\/fonc.2025.1703261","volume":"15","author":"Z Li","year":"2025","unstructured":"Li Z, Fang P, Shen S, Zhang L, Xie R, Li C. Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis. Front Oncol. 2025;15:1703261.","journal-title":"Front Oncol"},{"key":"8027_CR35","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.eclinm.2023.102240","volume":"64","author":"B Xu","year":"2023","unstructured":"Xu B, Pan Q, Pan H, Li H, Li X, Chen J, Pang D, Zhang B, Weng D, Peng R, et al. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2023;64:102240.","journal-title":"EClinicalMedicine"},{"key":"8027_CR36","doi-asserted-by":"publisher","first-page":"811687","DOI":"10.3389\/fonc.2022.811687","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Niu X, Wang Z, Cai Q, Tu C, Fan Z, Yao Y. Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial. Front Oncol. 2022;12:811687.","journal-title":"Front Oncol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-026-08027-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:28:09Z","timestamp":1781638089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12903-026-08027-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8027"],"URL":"https:\/\/doi.org\/10.1186\/s12903-026-08027-w","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Gansu Provincial Hospital (Approval No.: ec22c24093794353a3d5be41c0f1d86a). The patient signed a written informed consent for the anonymous use of his imaging and medical data for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient signed a written informed consent for the anonymous use of her imaging and medical data for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"500"}}